AGP Executive Report
Last update: 2 hours agoAdolescent Brain & Cannabis Research: A new Neuropsychopharmacology study links teen cannabis use—especially higher-potency products—to differences in dopamine-related brain systems tied to motivation and reward. Psychosis Risk Debate: Yale psychiatrist Deepak D’Souza weighs in on how cannabis exposure may raise psychosis risk in vulnerable people, with abstinence tied to better outcomes. Teen Risk-Taking Angle: A Nature Communications study suggests some teens may use substances like weed or alcohol to “get the system going” when dopamine reward biology is lower. Clinical Conversations Gap: Fewer than 1 in 5 older cannabis users report discussing use with clinicians, raising concerns for guidance and safety. Legal/Regulatory Watch: New Hampshire’s Gov. Kelly Ayotte vetoed a bill that would let medicinal dispensaries grow their own cannabis via on-site greenhouses. Industry/Business: Avicanna closed a non-brokered private placement to fund working capital and cannabinoid R&D. Retail Compliance: Ontario regulators ordered SNDL to divest de facto control of retail stores or face license action. Public Safety & Policy: Court rulings and ongoing state budget fights keep cannabis policy, enforcement, and public trust in the spotlight.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.